• 
  Fernanda Mosele, Elise Deluche, Amelie Lusque, Loïc Le Bescond, Thomas Filleron, et al.. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nature Medicine, 2023, 29 (8), pp.2110-2120. ⟨10.1038/s41591-023-02478-2⟩. ⟨hal-04265717⟩
• 
  Khalil Saleh, Matthieu Carton, Véronique Dieras, Pierre-Etienne Heudel, Etienne Brain, et al.. Impact of body mass index on overall survival in patients with metastatic breast cancer. Breast, 2021, 55, pp.16-24. ⟨10.1016/j.breast.2020.11.014⟩. ⟨hal-03345238⟩
• 
  F. Gauna, S. Carof, E Mouret‐fourme, I. Coupier, V. Mari, et al.. Links between gender norms and the intergenerational transmission of health information in parents carrying BRCA1/2 pathogenic variants. Journal of Genetic Counseling, 2023, Online ahead of print. ⟨10.1002/jgc4.1734⟩. ⟨inserm-04302095⟩
• 
  Thomas Grinda, Alison Antoine, William Jacot, Paul-Henri Cottu, Thibault de la Motte Rouge, et al.. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort. European Journal of Cancer, 2023, 189, pp.112935. ⟨10.1016/j.ejca.2023.05.023⟩. ⟨hal-04205902⟩
• 
  Lionel Falchero, Florian Guisier, Marie Darrason, Arnaud Boyer, Charles Dayen, et al.. Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study. Lung Cancer, 2023, 185, ⟨10.1016/j.lungcan.2023.107379⟩. ⟨hal-04229547⟩
• 
  Brice Paquette, Dewi Vernerey, Bruno Chauffert, Sandrine Dabakuyo, Loic Feuvret, et al.. Prognostic value of health‐related quality of life for death risk stratification in patients with unresectable glioblastoma. Cancer Medicine, 2016, 5 (8), pp.1753-1764. ⟨10.1002/cam4.734⟩. ⟨hal-03036055⟩
• 
  Thibault Escobar, Fanny Orlhac, Anne-Capucine Rollet, Olivier Humbert, Sebastien Vauclin, et al.. Radiomic decision maps reveal patterns discriminating between glioma progression and radiation-induced necrosis in static and dual time [18F]-FDOPA PET. Society of Nuclear Medicine and Molecular Imaging meeting, Jun 2022, Vancouver, Canada. ⟨hal-04248818⟩
• 
  P. Lesueur, J. Doyen, M. Lecornu, V. Calugaru, C. Florescu, et al.. Nouvelles indications de protonthérapie et essais cliniques en cours : tumeurs intracrâniennes. Cancer/Radiothérapie, 2021, 25 (6-7), pp.545-549. ⟨10.1016/j.canrad.2021.06.009⟩. ⟨hal-03318266⟩
• 
  Florent Milliet, Alexandre Bozec, Renaud Schiappa, Julien Viotti, Anouchka Modesto, et al.. Metachronous second primary neoplasia in oropharyngeal cancer patients: Impact of tumor HPV status. A GETTEC multicentric study. Oral Oncology, 2021, 122, pp.105503. ⟨10.1016/j.oraloncology.2021.105503⟩. ⟨hal-03627840⟩
• 
  Yann-Alexandre Vano, Réza Elaidi, Mostefa Bennamoun, Christine Chevreau, Delphine Borchiellini, et al.. Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncology, 2022, 23 (5), pp.612-624. ⟨10.1016/S1470-2045(22)00128-0⟩. ⟨hal-04072026⟩
• 
  Clémence Basse, Antoine Italiano, Nicolas Penel, Olivier Mir, Claire Chemin, et al.. Sarcomas in patients over 90: Natural history and treatment—A nationwide study over 6 years. International Journal of Cancer, 2019, 145 (8), pp.2135-2143. ⟨10.1002/ijc.32307⟩. ⟨hal-02504786⟩
• 
  Germán Reyes-Botero, Stéphanie Cartalat-Carel, Olivier Chinot, Maryline Barrie, Luc Taillandier, et al.. Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG). Oncologist, 2018, 23 (5), pp.524-e44. ⟨10.1634/theoncologist.2017-0689⟩. ⟨hal-01727451⟩
• 
  Fernanda Mosele, Elise Deluche, Amelie Lusque, Loïc Le Bescond, Thomas Filleron, et al.. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nature Medicine, 2023, 29 (8), pp.2110 - 2120. ⟨10.1038/s41591-023-02478-2⟩. ⟨hal-04187928⟩
• 
  P. Pautier, A. Floquet, C. Chevreau, N. Penel, C. Guillemet, et al.. A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery. ESMO Open, 2021, 6 (4), pp.100209. ⟨10.1016/j.esmoop.2021.100209⟩. ⟨hal-03623631⟩
• 
  D. Dano, A. Lardy-Cleaud, A. Monneur, N. Quenel-Tueux, C. Levy, et al.. Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME). ESMO Open, 2021, 6 (4), pp.100220. ⟨10.1016/j.esmoop.2021.100220⟩. ⟨hal-03426433⟩
• 
  Joël Castelli, Juliette Thariat, Karen Benezery, Ali Hasbini, Bernard Gery, et al.. Weekly Adaptive Radiotherapy vs Standard Intensity-Modulated Radiotherapy for Improving Salivary Function in Patients With Head and Neck Cancer. JAMA oncology, 2023, pp.e231352. ⟨10.1001/jamaoncol.2023.1352⟩. ⟨hal-04117942⟩
• 
  Izabella Zahradnik, Michal Pomorski, Ludovic de Marzi, Dominique Tromson, Philippe Barberet, et al.. scCVD diamond membrane based microdosimeter for hadron therapy. physica status solidi (a), 2018, 215 (22), pp.1800383. ⟨10.1002/pssa.201800383⟩. ⟨cea-04146874⟩
• 
  Maud Maillard, Manon Launay, Bernard Royer, Jérome Guitton, Elodie Gautier-Veyret, et al.. Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency. British Journal of Clinical Pharmacology, 2022, Global Pharmacovigilance, 89 (5), pp.762-772. ⟨10.1111/bcp.15536⟩. ⟨hal-03789849⟩
• 
  Jérôme Fayette, Joël Guigay, Christophe Le Tourneau, Marian Degardin, Frédéric Peyrade, et al.. Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: Phase II UNICANCER trial ORL03. Oncotarget, 2017, 8 (31), pp.51830-51839. ⟨10.18632/oncotarget.15901⟩. ⟨hal-02558669⟩
• 
  Dorian Culié, Renaud Schiappa, Anouchka Modesto, Julien Viotti, Emmanuel Chamorey, et al.. Upfront surgery or definitive radiotherapy for p16+ oropharyngeal cancer. A GETTEC multicentric study. EJSO - European Journal of Surgical Oncology, 2021, In press, ⟨10.1016/j.ejso.2020.12.011⟩. ⟨hal-03166902⟩

109

172